Literature DB >> 17657490

Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells.

Despina Rudolf1, Tobias Silberzahn, Steffen Walter, Dominik Maurer, Johanna Engelhard, Dorothee Wernet, Hans-Jörg Bühring, Gundram Jung, Byoung S Kwon, Hans-Georg Rammensee, Stefan Stevanović.   

Abstract

The in vitro generation of cytotoxic T lymphocytes (CTLs) for anticancer immunotherapy is a promising approach to take patient-specific therapy from the bench to the bedside. Two criteria must be met by protocols for the expansion of CTLs: high yield of functional cells and suitability for good manufacturing practice (GMP). The antigen presenting cells (APCs) used to expand the CTLs are the key to achieving both targets but they pose a challenge: Unspecific stimulation is not feasible because only memory T cells are expanded and not rare naïve CTL precursors; in addition, antigen-specific stimulation by cell-based APCs is cumbersome and problematic in a clinical setting. However, synthetic artificial APCs which can be loaded reproducibly with MHC-peptide monomers and antibodies specific for costimulatory molecules could resolve these problems. The purpose of this study was to investigate the potential of complex synthetic artificial APCs in triggering the costimulatory molecules CD28 and 4-1BB on the T cell. Anti-4-1BB antibodies were added to an established system of microbeads coated with MHC-peptide monomers and anti-CD28. Triggering via CD28 and 4-1BB resulted in strong costimulatory synergy. The quantitative ratio between these signals determined the outcome of the stimulation with optimal results when anti-4-1BB and anti-CD28 were applied in a 3:1 ratio. Functional CTLs of an effector memory subtype (CD45RA(-) CCR7(-)) were generated in high numbers. We present a highly defined APC platform using off-the-shelf reagents for the convenient generation of large numbers of antigen-specific CTLs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17657490     DOI: 10.1007/s00262-007-0360-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study.

Authors:  Stephen E Wright; Kathleen A Rewers-Felkins; Imelda S Quinlin; Catherine A Phillips; Mary Townsend; Ramila Philip; Mark J Dobrzanski; Pamela R Lockwood-Cooke; William Robinson
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

2.  Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles.

Authors:  John W Hickey; Jonathan P Schneck
Journal:  J Vis Exp       Date:  2018-11-17       Impact factor: 1.355

Review 3.  Genetic engineering of T cells for adoptive immunotherapy.

Authors:  Angel Varela-Rohena; Carmine Carpenito; Elena E Perez; Max Richardson; Richard V Parry; Michael Milone; John Scholler; Xueli Hao; Angela Mexas; Richard G Carroll; Carl H June; James L Riley
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer.

Authors:  Susan B Ingersoll; Sarfraz Ahmad; Hasina C McGann; Robert K Banks; Nicole M Stavitzski; Milan Srivastava; Ghazanfar Ali; Neil J Finkler; John R Edwards; Robert W Holloway
Journal:  Mol Cell Biochem       Date:  2015-06-06       Impact factor: 3.396

Review 5.  Surface engineering for lymphocyte programming.

Authors:  Elana Ben-Akiva; Randall A Meyer; David R Wilson; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2017-05-10       Impact factor: 15.470

6.  Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement.

Authors:  Kevin M Friedman; Laura E Devillier; Steven A Feldman; Steven A Rosenberg; Mark E Dudley
Journal:  J Immunother       Date:  2011 Nov-Dec       Impact factor: 4.456

Review 7.  Nanoscale artificial antigen presenting cells for cancer immunotherapy.

Authors:  Kelly R Rhodes; Jordan J Green
Journal:  Mol Immunol       Date:  2018-03-07       Impact factor: 4.407

8.  Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells.

Authors:  Matthias Wölfl; Philip D Greenberg
Journal:  Nat Protoc       Date:  2014-03-27       Impact factor: 13.491

9.  The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.

Authors:  Simon Walz; Juliane S Stickel; Daniel Johannes Kowalewski; Heiko Schuster; Katja Weisel; Linus Backert; Stefan Kahn; Annika Nelde; Tatjana Stroh; Martin Handel; Oliver Kohlbacher; Lothar Kanz; Helmut Rainer Salih; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Blood       Date:  2015-07-02       Impact factor: 22.113

Review 10.  Biomimetic delivery with micro- and nanoparticles.

Authors:  Stephen C Balmert; Steven R Little
Journal:  Adv Mater       Date:  2012-04-23       Impact factor: 30.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.